Carole Johnson Takes Charge of HRSA and the 340B Program

Carole Johnson's tenure as HRSA administrator officially began this week Tuesday.

The U.S. Health Resources and Services Administration (HRSA), the agency that runs the 340B drug pricing program, has a permanent leader again for the first time in almost a year.

Carole Johnson started in her position as HRSA administrator on

Read More »

California Asks Judge to Reject 340B Community Health Centers’ Request to Stop Medicaid Drug Payment Change

California's state health department asked a judge yesterday to reject 340B community health centers' request to halt a major state Medicaid drug reimbursement change that began on Jan. 1.

Federally qualified health clinics in California have no right to sue to stop a major state Medicaid drug reimbursement change that began on Jan. 1., the state Department of Health Care Services (DHCS) argued in a legal brief filed Wednesday.

Read More »

Drug Makers Want to Halt 340B Dispute Resolution Proceedings, Citing Lawsuits and Forthcoming Rule

Timeout
AstraZeneca and Sanofi have asked 340B administrative dispute resolution panels to pause covered entities’ ADR proceedings against them.

Drug manufacturers AstraZeneca and Sanofi have asked 340B administrative dispute resolution panels to pause covered entities’ ADR proceedings against them until all 340B-related federal court litigation is finished and until after the government finalizes its forthcoming new 340B ADR regulation.

Read More »

Feds Back and Kalderos Resists Pausing Company’s 340B Lawsuit

Kalderos says in a lawsuit that the federal government's 340B contract pharmacy policy is keeping it from effectively marketing its 340B Pay service to let drug companies provide 340B pricing as a post-purchase rebate rather than as a price discount.

The federal government told a judge in late December its appeal of her joint ruling in Novartis and United Therapeutics’ (UT) 340B contract pharmacy lawsuits justifies her pausing drug industry vendor Kalderos’ 340B contract pharmacy suit.

Kalderos told the judge

Read More »

Biden Axing Trump’s “Most Favored Nation” Drug Pricing Rule that 340B Entities and Pharma Both Disliked

The Biden administration is rescinding ex-President Trump's unimplemented most favored nation drug pricing rule, which was disliked by 340B entities and drug manufacturers.

The Biden administration is rescinding an unimplemented Trump-era regulation that would have pegged Medicare Part B drug reimbursement for 50 expensive, physician-administered drugs on the lowest price that drug manufacturers provide in similar countries.

The U.S. Centers for Medicare &

Read More »

Three Big Predictions for the 340B Program in 2022

340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022 in his latest monthly column for Omnicell’s blog.

In his monthly column for Omnicell’s blog, 340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022. They focus on:

  • the U.S. Supreme Court case on Medicare reimbursement to 340B
Read More »

News Alert: Calif. 340B Health Centers Ask Judge to Stop Tomorrow’s “Devastating” State Medicaid Drug Payment Changes

California health centers asked U.S. District Judge John A. Mendez yesterday to stop a state Medicaid drug reimbursement change due to begin tomorrow that they say would strip away all their 340B drug discount savings.

California health centers asked a federal district judge yesterday to stop a major state Medicaid drug reimbursement change due to begin tomorrow. They say the change would strip away all their 340B drug discount savings, devastating safety-net health care

Read More »

Breaking News

Breaking News: AbbVie Becomes 11th Drug Maker to Restrict 340B Contract Pharmacy. Feds Appeal Rulings in Lilly, Novo Nordisk, and Sanofi Cases.

AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to covered entities subject to such exclusions.

Biopharmaceutical company AbbVie—maker of the expensive and widely prescribed immunosuppressive medication Humira—today became the 11th drug manufacturer to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.

Starting Feb. 1, AbbVie will require hospitals to submit claims

Read More »

Breaking News

Breaking News: Feds Appeal Rulings in Novartis and United Therapeutics 340B Contract Pharmacy Cases

The federal government yesterday asked the federal appeals court in Washington, D.C., to review a lower court's Nov. 5 joint ruling in Novartis and United Therapeutics' 340B contract pharmacy lawsuits.

The federal government late yesterday filed notice that it is appealing a federal judge’s joint ruling in two cases last month that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and other health care providers

Read More »

John Thune, Senate’s No. 2 Republican and Strong 340B Provider Ally, Weighs Retirement

U.S. Senate Minority Whip John Thune (R-S.D.), a strong 340B covered entity ally, is considering not running for re-election in 2022. | Gage Skidmore/Flickr

South Dakota U.S. Sen. John Thune, the second-ranking Senate Republican and a long-time 340B covered entity ally, might not run for re-election in 2022, two news organizations report.  It would be a significant blow to 340B providers who have counted

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live